Travere Therapeutics, Inc.
San Diego, CA
- UEI
- JUBZMHK84S36
- CAGE
- 77HN5
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3611 Valley Centre Dr Suite 300, San Diego, CA 92130, USA
- Website
- travere.com
- Founded
- 2020
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $27,482 |
| FY2026 | $323,917 |
| FY2025 | $334,938 |
| FY2024 | $656,685 |
| FY2023 | $640,399 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $351,399 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| United Therapeutics Corp | Silver Spring, MD | 325412 Pharmaceutical Preparation Manufacturing |
| Amneal Pharmaceuticals Of New York, LLC | Medford, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Hygen Pharmaceuticals Inc. | Redmond, WA | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| Arrowhead Pharmaceuticals, Inc. | Pasadena, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Vifor (International) AG | St. Gallen, SG | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Travere Therapeutics, Inc., a San Diego-based biopharmaceutical manufacturer, supplies rare-disease pharmaceuticals to the Department of Veterans Affairs as a prime contractor under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), competing on full-and-open terms with no SBA set-aside designations. The company holds 92 prime awards across ten distinct customer agencies, all issued without subcontracting; it does not operate as a subcontractor.
Travere's federal footprint is narrowly concentrated within the VA health system. The Department of Veterans Affairs accounts for the entire customer base, with the VA National Acquisition Center anchoring the portfolio by potential value—four awards worth $50.2 million combined, primarily $25 million Blanket Purchase Agreements for Thiola (tiopronin) and Cholbam (chenodeoxycholic acid)—while Veterans Integrated Service Networks drive volume through recurring small delivery orders. VISN 5 leads by order count with 47 awards worth $1.1 million combined potential value; VISN 12 holds 11 awards worth $25.6 million; VISN 10 places 10 awards worth $1.7 million; and VISN 21 issues 10 awards totaling $174 thousand. The divergence between rankings reflects the BPA structure: National Acquisition Center awards establish high-dollar indefinite vehicles that VISNs then call against with smaller firm fixed-price delivery orders for specific medications and quantities. Representative work includes a $131,523.01 emergency Thiola 100 mg order from VISN 22 in February 2026; recurring monthly delivery orders from VISN 5 in the $11,000 to $31,000 range for Thiola 100 mg, Filspari 200 mg and 400 mg, and related products; a $236,500 purchase order from VISN 10 for Chenodal 250 mg; and a $200,552 purchase order from VISN 10 for Chenodal 250 mg.
Travere holds position on the Pharmaceuticals and Drugs FSS schedule, which carries 84 task orders worth $52.2 million combined potential value. Activity has trended upward—9 awards in 2022 to 17 in 2024—though 2025 dropped to 5 awards and 2026 has returned to 9. Only one award faces ultimate completion in the next twenty-four months (combined potential value $132 thousand), creating minimal recompete exposure. Travere's product portfolio centers on rare-disease therapies for kidney and liver disorders: Thiola for cystinuria, Filspari for primary glomerulonephritis, Cholbam for progressive familial intrahepatic cholestasis and bile acid synthesis defects, and Chenodal for gallstone prevention in patients with liver dysfunction. Place of performance spans San Diego (headquarters), Foster City, Monroeville, Pennsylvania, and Bartlett, Tennessee.
Quick answers
Is Travere Therapeutics, Inc. registered in SAM.gov?
Yes. Travere Therapeutics, Inc.'s SAM.gov registration is active through December 10, 2026.
Which contract vehicles does Travere Therapeutics, Inc. hold?
Travere Therapeutics, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Travere Therapeutics, Inc. received in federal contracts?
Federal contracts obligated $334,938 to Travere Therapeutics, Inc. in fiscal year 2025 and $1,983,420 in fiscal years 2023 through 2027.
What is Travere Therapeutics, Inc.'s most recent federal award?
Travere Therapeutics, Inc.'s most recent federal contract award is Thiola 100 MG (36C24527P0072), from Veterans Integrated Service Network 5 (VHA), on October 22, 2026.
On GovTribe
See Travere Therapeutics, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors